Table 4.
Multivariate analysis of distant metastasis in patients with breast cancer who received neoadjuvant chemotherapy followed by total mastectomy.
| Distant metastasis |
||||
|---|---|---|---|---|
| HR | (95% CI) | p value | ||
| PMRT | No | Ref | 0.33 | |
| Yes | 0.91 | (0.77–1.21) | ||
| Age | 20–49 | Ref | 0.37 | |
| 50+ | 0.89 | (0.88–1.21) | ||
| Diagnosis year | 2007–2010 | Ref | 0.45 | |
| 2011–2015 | 0.93 | (0.73–1.16) | ||
| CCI scores | 0 | Ref | 0.1386 | |
| 1 | 1.22 | (0.87–1.69) | ||
| 2+ | 1.43 | (0.23–1.89) | ||
| Differentiation | Poor | Ref | 0.0039 | |
| Moderate | 0.78 | (0.39–0.85) | ||
| Well | 0.69 | (0.35–0.79) | ||
| AJCC clinical stages | I | Ref | 0.0048 | |
| II | 1.29 | (0.97–1.69) | ||
| III | 1.34 | (0.82–2.20) | ||
| IV | 1.77 | (1.19–2.39) | ||
| ypT | ypT0 | Ref | <0.0001 | |
| ypT1 | 1.90 | (0.94–3.66) | ||
| ypT2 | 2.73 | (1.45–5.51) | ||
| ypT3–4 | 4.41 | (2.21–7.87) | ||
| ypN | ypN0 | Ref | <0.0001 | |
| ypN1 | 1.19 | (1.11–1.59) | ||
| ypN2–3 | 1.28 | (1.07–2.90) | ||
| NACT regimen | Anthracycline | Ref | 0.89 | |
| Taxanes | 0.98 | (0.74–1.39) | ||
| Both | 1.04 | (0.78–1.30) | ||
| Neither | 1.01 | (0.72–1.46) | ||
| Nodal surgery | SLNB | Ref | 0.1098 | |
| ALND | 1.08 | (0.91–1.43) | ||
| ER/PR positive | Negative | Ref | 0.35 | |
| Positive | 1.13 | (0.90–1.44) | ||
| HER2 positive | Negative | Ref | <0.0001 | |
| Positive | 1.80 | (1.39–2.21) | ||
| Hospital level | Academic | Ref | 0.26 | |
| Others | 0.87 | (0.69–1.12) | ||
HR, hazard ratio; CI, confidence interval; PMRT, postmastectomy radiation therapy; T, tumor; N, nodal; NACT, neoadjuvant chemotherapy; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; ALND, axillary lymph node dissection; SLNB, sentinel lymph node biopsy; CCI, Charlson comorbidity index; AJCC, American Joint Committee on Cancer; ypT, postchemotherapy pathologic tumor stages; ypN, postchemotherapy pathologic nodal stages.